Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CTSD | P07339 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.51 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.50 |
| ▸ | DHFR | P00374 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8134814 | 0.79 | FGFR1 (0.66) | NPC1RAB9AMEN1KMT2ACTSD | |
| SCHEMBL30395230 | 0.79 | TDP1 (0.59) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL5745605 | 0.79 | TDP1 (0.59) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL16739392 | 0.79 | NPC1 (0.54) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL1767756 | 0.77 | MEN1 (1.00) | NPC1RAB9AMEN1KMT2AATM | |
| Hydrochloric Acid SCHEMBL27573278 | 0.77 | TDP1 (0.57) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL22509830 | 0.76 | NPC1 (0.55) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL8574353 | 0.76 | KMT2A (0.74) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL28850708 | 0.75 | HPGD (0.48) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL28229302 | 0.75 | ALDH1A1 (0.53) | NPC1RAB9AKMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822485-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130018064-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2013-01-17 | — | — | US | disclosed |
| EP-2504330-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011063272-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018064-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APP | NPC1 1927/4885RAB9A 1150/4885MEN1 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.